The purpose of this review was to identify and synthesise the existing evidence on effectiveness of interventions targeting people who inject drugs at two stages of the care cascade: linkage to care and adherence to treatment of HIV, hepatitis B/C and TB.
This report documents the process and outcome of the assessment and translation of the evidence into guidance recommendations on linkage to care and/or adherence to treatment for HCV, HIV and TB for the ECDC technical report, ‘A systematic literature review of interventions to increase linkage to care and adherence to treatment for hepatitis B and C, HIV and tuberculosis among people who inject drugs’.
Clusters and outbreaks of hepatitis A virus (HAV) genotype IB with four unique but closely related HAV sequences have been reported in six European Union (EU) countries and in the United Kingdom (UK).
For 2020, 28 EU/EEA countries reported 4 824 confirmed cases of Shiga toxin -producing Escherichia coli (STEC) infection. The overall notification rate was 1.6 cases per 100 000 population. The highest notification rates were reported in Ireland, Malta, Denmark, and Norway. The EU/EEA notification rate decreased notably in 2020 compared with 2016-2019 due to the COVID-19 pandemic.
In 2020, 13 914 cases of hepatitis C were reported in 28 EU/EEA Member States. Excluding countries that only reported acute cases leaves 13 901 cases, which corresponds to a crude rate of 3.9 cases per 100 000 population.